Sweden's MASAI trial showed AI can safely replace one of two radiologists. Rolling it out region by region in a randomised order would prove it works at national scale and that interval cancers do not rise.
MASAI (Lund) demonstrated a 44% workload reduction and higher cancer detection with AI-supported reading. Rather than piecemeal adoption, propose national programmes adopt in a randomised stepped-wedge order so every region serves as its own control, with interval cancer rate and recall rate as co-primary endpoints.
AI can take over one reader's work in double-reading screening programmes while finding more cancers. Whether the extra cancers found are ones that would have harmed women, and whether interval cancers fall, is the question the trial's primary endpoint will answer.
One bottleneck page and 32 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload, Lunit, Mammography & tomosynthesis, AI in radiology.
Shares Lunit, Early detection of cancer, AI in radiology, Not enough oncologists, nurses, pathologists, physicists.
Shares MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload, Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Shares Lunit, Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Shares Lunit, Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Shares MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload, Mammography & tomosynthesis, AI in radiology, The hardest cancers are found late.
Shares Lunit, Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.
Shares Mammography & tomosynthesis, AI in radiology, HR-positive / HER2-negative breast cancer.